Press and Media

[WASHINGTON, D.C., July 5, 2023] —Today, Responsum Health (Responsum), an innovative developer of personalized health knowledge apps and digital patient communities, announced a partnership with Aldeyra Therapeutics on a new project to provide patient recruitment services for The ADRO Trial: An Adaptive, 2-Part, Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Adults With Atopic Dermatitis.

[WASHINGTON, D.C., May 24, 2023]—Today, Responsum Health announced a new partnership with Let’s Talk Menopause, a national nonprofit organization whose mission it is to change the conversation around menopause so that women get the information they need and the healthcare they deserve.

[WASHINGTON, D.C., April 27, 2023] — Today, Responsum Health announced a new partnership with the Society for Women’s Health Research to solicit women’s perspectives in order to create a uniquely impactful digital toolkit.

[WASHINGTON, D.C., February 21, 2023]—Today, Responsum Health announced another collaboration with Aldeyra Therapeutics, this time to support the Renovel Study, a Phase 2 clinical trial investigating an experimental drug (ADX-629) in people with nephrotic syndrome (NS), including minimal change disease and focal segmental glomerulosclerosis.

[WASHINGTON, D.C., July 7, 2022]—Today, Responsum Health announced an exciting partnership with the Society for Women’s Health Research (SWHR), a national nonprofit dedicated to meeting needs and closing research gaps in women’s health issues, to expand the reach and improve the content of the Responsum for Fibroids community.

[WASHINGTON, D.C., Aug. 25, 2022] — Today, Responsum Health announced an exciting partnership with Aldeyra Therapeutics to raise clinical trial awareness and support patient recruitment for patients with chronic cough and retinitis pigmentosa.

[WASHINGTON, D.C., Apr. 14, 2022] —Today, Responsum Health announced a new partnership with Solve M.E., a non-profit organization that serves as a catalyst for critical research into diagnostics, treatments, and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID, and other post-infection diseases.

[WASHINGTON, D.C., March 23, 2022] —Responsum Health, in partnership with the Academy for Continued Healthcare Learning (ACHL), has created and launched an online connection and knowledge platform for women living with menopausal symptoms.

[WASHINGTON, D.C., March 21, 2022] —Responsum Health is excited to announce that it has signed an agreement with Citeline Connect to identify and share clinical trial opportunities with members of its various online communities, including chronic kidney disease and long COVID.

[WASHINGTON, D.C., March 1, 2022] —Both Glaukos and Santen Pharmaceutical Co., Ltd., have provided grants to Prevent Blindness, the nation’s oldest eye health and safety non-profit organization, in support of The Glaucoma Community by Prevent Blindness, a patient knowledge app and online community of more than 2,000 individuals, launched in partnership with Responsum Health.

[WASHINGTON, D.C., January 27, 2022] —A new report published this week by one of the country’s most respected startup analytics firms, KingsCrowd, offered a glowing assessment of Responsum’s prospects. Currently, Responsum Health is raising funds from interested investors on the private investing platform site Republic to fuel an aggressive business development plan.

[WASHINGTON, D.C., October 27, 2021] — Responsum Health announced today that its fast-growing long-COVID patient community surpassed 2,000 members. The unique Responsum patient knowledge app platform, which provides a continuously updated newsfeed of article summaries curated from across the Internet, was launched in April of this year. It is available for free in the App Store, Google Play, and the Responsum Health website.

[WASHINGTON, D.C., September 8, 2021] — Responsum Health is pleased to announce that it has exceeded its initial $25,000 goal for its crowd-sourced fundraising campaign on the Republic investment platform. This “friends and family” pre-round represents a key preliminary milestone for the company and will qualify Responsum for full engagement from Republic and its community of over 800,000 individual investors.

[WASHINGTON, D.C., August 30, 2021] —Responsum Health (Responsum) is pleased and excited to announce the launch of its new public investment opportunity campaign. After years of continued growth, including the launch of five new healthcare support apps that currently serve more than 10,000 members and the formation of various partnerships with key players across the healthcare landscape, Responsum is poised to take another step forward in our mission of supporting and empowering patients, caregivers, advocates and providers, alike through the expansion of digital health literacy resources.

[WASHINGTON, D.C., July 12, 2021] — Today, Responsum Health (Responsum) announced that its recently launched knowledge platform for COVID-19 “long haulers” (Responsum for Long COVID) had quickly grown to over 1000 members. The app’s analytics further show incredibly high levels of user activity and demonstrate an unprecedented demand for the tool from people suffering with long-term health effects of COVID-19.

[WASHINGTON, D.C., April 24, 2021] — Today, Real Housewives of Atlanta star Cynthia Bailey-Hill announced her support for Responsum for Fibroids, an online empowerment, knowledge, and support platform for women with uterine fibroids, a condition that affects 70-80% of all women by the age of 50.

[WASHINGTON, D.C., Apr. 8, 2021] — Today, Responsum Health (Responsum), an innovative developer of personalized patient apps and chronic disease knowledge communities, announced the launch of a new platform and mobile app to support people experiencing lasting symptoms or complications from the novel coronavirus (COVID-19).